Magenta Therapeutics Inc MGTA:NASDAQ

Last Price$0.79NASDAQ Previous Close - Last Trade as of 4:00PM ET 3/24/23
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$0.78 (6)
Ask (Size)$0.78 (5)
Day Low / HighN/A - N/A
Volume215.9 K
  • Latest Stories
  • Commentary and Analysis
--HC Wainwright Initiates Magenta Therapeutics at Neutral
9:37AM ET 2/28/2023 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Rapid January Jobs Growth and Weak Tech Earnings Weigh on US Equity Futures
9:07AM ET 2/03/2023 MT Newswires

US equities were set to open in red territory Friday, with futures of the technology-heavy Nasdaq Composite leading the losses following lackluster...

Top Premarket Gainers
7:50AM ET 2/03/2023 MT Newswires

Genetic Technologies (GENE) shares soared 171% after detailing plans to launch a simple saliva-based test kit to evaluate a women's risk of developing...

--BTIG Downgrades Magenta Therapeutics to Neutral From Buy
12:07PM ET 1/26/2023 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Cowen Downgrades Magenta Therapeutics to Market Perform From Outperform
9:59AM ET 1/26/2023 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Top Premarket Decliners
8:06AM ET 1/26/2023 MT Newswires

Ocuphire Pharma (OCUP) shares dropped 26%, a day after the company said the phase 2 trial of its oral diabetic retinopathy drug candidate did not meet the...

Wedbush Downgrades Magenta Therapeutics to Neutral From Outperform on MGTA-117 Safety Issues, Lowers Price Targe to $1 From $3
7:47AM ET 1/26/2023 MT Newswires

Wedbush downgrades Magenta Therapeutics (MGTA) to neutral from outperform after the company decided to pause its dose escalation study of MGTA-117 in...

--BTIG Lowers Price Target on Magenta Therapeutics to $3 From $6, Maintains Buy Rating
9:11AM ET 12/21/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Top Midday Decliners
2:06PM ET 12/20/2022 MT Newswires

Entrada Therapeutics (TRDA) shares plunged Tuesday after yesterday saying the US Food and Drug Administration placed a clinical hold on the investigational...

Magenta Therapeutics Says it Stopped Group Four Dosing in MGTA-117 Trial; Shares Plunge
11:08AM ET 12/20/2022 MT Newswires

Magenta Therapeutics (MGTA) said Tuesday it will not dose participants at the group four dosing level for its MGTA-117 phase 1/2 dose escalation trial in...